1. The Effect of Renal Failure on the Disposition and Neuromuscular Blocking Action of Pancuronium Bromide
A.A. Somogyi , C.A. Shanks, and E. J. Triggs. Europ. J. clin. Pharmacol. 12, 23-29 (1977)
This study was designed to evaluate simultaneously the pharmacokinetics and neuromuscular blocking action of pancuronium bromide in patients with poor renal function, and to compare the results with normal patients, as well as to determine the appropriate pharmacokinetic model consistent with the results obtained.
2. Cholinesterase inhibition based determination of pancuronium bromide in biological samples
Vesna P. Stankov-Jovanović, Snežana D. Nikolić-Mandić, Ljuba M. Mandić, Violeta D. Mitić. Anal Bioanal Chem (2006) 385: 1462–1469
As pancuronium bromide is used as a neuromuscular blocking agent during surgical procedures, it was very important to control the anaesthetic dose. Therefore, for the purpose of its quantification in serum or urine, a rapid kinetic method, based on the inhibition of cholinesterase (with benzoylcholine as the substrate), was developed and validated. The applicability of the method was tested by quantification of PCBr in model urine and serum samples, as well as in a urine sample taken during surgery. In order to minimize the interferences of serum cholinesterase, urine proteins and certain small molecules (urea, creatinine, uric and hippuric acid) in real samples, two methods for the separation of PCBr from samples were applied: (1) denaturation of proteins with HCl and centrifugation, (2) gel-chromatographic separation of PCBr. Results obtained by gel-chromatography of samples, particularly those with low PCBr concentrations, were less precise compared to the results obtained by HCl treatment. For this reason, as well as the fact that gel-chromatography is a time-consuming method, we propose the already mentioned method for the elimination of interfering substances by HCl as the better one.